肝细胞癌患者TACE术后血清GP73、FOXP3表达及其与疗效的关系

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)患者经肝动脉化疗栓塞(TACE)治疗后血清高尔基体蛋白73(GP73)、叉头状螺旋转录因子(FOXP3)表达变化及其与疗效的关系。方法选取2019年5月至2021年8月在同济医学院附属同济医院接受TACE治疗的HCC患者198例。按照临床疗效判定标准将患者分为有效组(n=122)、无效组(n=76),对比两组患者治疗后GP73及FOXP3水平;分析GP73、FOXP3表达与临床疗效的关系;根据预后结局分为预后良好组(n=104)及预后不良组(n=94)。多元logistic分析影响预后的危险因素;ROC评估GP73、FOXP3联合检测对HCC患者的预后评估效能。结果有效组患者TACE治疗后的GP73、FOXP3表达显著低于无效组分别为158.67±69.53比179.73±61.35、0.65±0.18比0.77±0.20(P<0.05)。Spearman相关系数显示GP73、FOXP3表达与临床疗效之间均呈显著负相关(r=-0.662、-0.688,P<0.05);经Logistic回归结果显示,Child-Pugh分级、GP73、FOXP3是影响HCC患者预后的危险因素。联合GP73、FOXP3检测的曲线下面积为0.834,显著高于单一检测的0.653、0.597(Z=4.415、5.660,均P<0.01),敏感度为87.23%、特异度为85.58%。结论血清GP73、FOXP3表达与HCC患者TACE的疗效及预后均具有重要关联,联合GP73、FOXP3检测可提高对HCC患者预后的评估。

关键词: 肝细胞癌, 肝动脉化疗栓塞, 高尔基体蛋白73, 叉头状螺旋转录因子, 疗效及预后

Abstract: Objective To investigate the changes in serum Golgi body protein 73 (GP73) and forkhead spiral transcription factor (FOXP3) expression in patients diagnosed with hepatocellular carcinoma (HCC) after hepatic arterial chemoembolization (TACE) treatment. Additionally, we aim to determine the correlation between these changes and treatment effectiveness as well as prognosis.Methods A total of 198 HCC patients who underwent TACE treatment in our hospital from May 2019 to August 2021 were retrospectively selected as subjects. All patients received TACE treatment and were divided into two groups based on clinical efficacy criteria: an effective group (n=122) and an ineffective group (n=76). After treatment, we compared the levels of GP73 and FOXP3 between the two groups and analyzed the relationship between GP73 and FOXP3 expression and clinical efficacy. Furthermore, all patients were divided into a good prognosis group (n=104) and a poor prognosis group (n=94) based on the outcome. Multivariate Logistic analysis was performed to identify the risk factors that affect prognosis. Finally, we evaluated the predictive effect of GP73 and FOXP3 combined detection on the prognosis of HCC patients using ROC analysis.Results After TACE treatment, the expression of GP73 and FOXP3 in the effective group was significantly lower than that in ineffective group (158.67±69.53 vs. 179.73±61.35, 0.65±0.18 vs. 0.77±0.20 respectively, P<0.05). According to the Spearman correlation coefficient, a significantly negative correlation was observed between GP73 and FOXP3 expression and clinical efficacy (r=-0.662, -0.688, P<0.05) . Logistic regression analysis showed that Child-Pugh grade, GP73 and FOXP3 were risk factors influencing the prognosis of HCC patients. The ROC curve showed that the area under the curve of combined GP73 and FOXP3 detection was significantly higher than that of single detection (ZGP73-combined =4.415, ZFOXP3-combined =5.660, both P<0.001), with a sensitivity of 87.23% and specificity of 85.58%.Conclusion The expression of GP73 and FOXP3 in serum is significantly associated with the efficacy and prognosis of HCC patients after TACE. The combined detection of GP73 and FOXP3 can be used to improve the prognosis assessment of HCC patients.

Key words: Hepatocellular carcinoma, Hepatic artery chemoembolization, Golgi apparatus protein 73, Fork-head helical transcription factor, Efficacy and prognosis

LEE EUNJI, 刘博, 袁响林. 肝细胞癌患者TACE术后血清GP73、FOXP3表达及其与疗效的关系[J]. 肝脏, 2023, 28(11): 1319-1322.

LEE EUNJI, LIU Bo, YUAN Xiang-lin. Relationship between serum GP73 and FOXP3 levels and efficacy and prognosis of hepatocellular carcinoma patients with TACE[J]. Chinese Hepatolgy, 2023, 28(11): 1319-1322.

参考文献

[1] Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019,156(2):477-491.
[2] Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021;149(1):1-61.
[3] Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis[J]. JAMA Oncol, 2020,6(12):204930.
[4] Wei ZQ, Zhang YW. Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit[J]. Chin Med J (Engl), 2021,134(19):2275-2286.
[5] Shao Z, Liu X, Peng C, et al. Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review[J]. World J Surg Oncol, 2021,19(1):293.
[6] Granito A, Muratori L, Lalanne C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in the immune microenvironment[J]. World J Gastroenterol, 2021,27(22):2994-3009.
[7] Liu Y, Wang J, Yang R, et al. GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells[J]. Oncogenesis, 2021,10(10):69.
[8] 国家卫生健康委办公厅.原发性肝癌诊疗指南(2022年版)[J].中华外科杂志,2022,60(4):273-309.
[9] Chwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee[J]. Eur J Cancer. 2016,62(1):132-7.
[10] Vogel A, Meyer T, Sapisochin G,et al. Hepatocellular carcinoma[J]. Lancet. 2022,400(10360):1345-1362.
[11] Lee YH, Tai D, Yip C, et al. Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond[J]. Front Immunol. 2020,30(11):568759.
[12] Gilles H, Garbutt T, Landrum J. Hepatocellular carcinoma[J]. Crit Care Nurs Clin North Am. 2022,34(3):289-301.
[13] Yuan P, Wang F, Zhu G, et al. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma[J]. Invest New Drugs. 2021,39(5):1383-1388.
[14] Liu B, Zhang Y, Chen H, et al. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma[J]. Cochrane Database Syst Rev. 2022,1(1):13345.
[15] 闫伟, 戴雪娥, 邢晓宇,等. 肝癌患者TACE治疗前后血清免疫炎症相关因子的变化及意义[J]. 中国肿瘤临床与康复,2022,29(3):269-273.
[16] Fang YS, Wu Q, Zhao HC, et al. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2021,15(9):1065-1076.
[17] Liu Y, Zhou S, Shi J, et al. c-Myc transactivates GP73 and promotes metastasis of hepatocellular carcinoma cells through GP73-mediated MMP-7 trafficking in a mildly hypoxic microenvironment[J]. Oncogenesis, 2019,8(10):58.
[18] Gong Z, Jia H, Yu J,et al. Nuclear FOXP3 inhibits tumor growth and induced apoptosis in hepatocellular carcinoma by targeting c-Myc[J]. Oncogenesis, 2020,9(10):97.
[19] Zhang H, Chen Y, Liao W, et al. FOXP3 expression in FOXP3+ tumor cells promotes hepatocellular cells metastasis[J]. Transl Cancer Res, 2020,9(10):5868-5881.
[20] Troisi RI, Berardi G, Morise Z, et al. Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study[J]. Br J Surg, 2021,108(2):196-204.